Company news

Veracyte, Inc. news in 2026

Veracyte, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026

November 2, 2026

Veracyte to Participate in Upcoming Investor Conferences

October 29, 2026

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

October 23, 2026

Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

October 19, 2026

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

October 16, 2026

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

October 14, 2026

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 29, 2026

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

September 25, 2026

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

September 14, 2026

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026

Veracyte Announces Second Quarter 2026 Financial Results

July 30, 2026

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

July 9, 2026

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

June 1, 2026

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

May 29, 2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

May 29, 2026

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

May 22, 2026

Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

May 15, 2026

Veracyte Announces First Quarter 2026 Financial Results

May 5, 2026

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

April 27, 2026

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

April 14, 2026

Veracyte Names Kevin Haas as Chief Development and Technology Officer

March 16, 2026

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

February 24, 2026

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

February 23, 2026

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

February 4, 2026

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

January 11, 2026

Calls in 2026

Decks in 2026